Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | ERCC1 | P07992 | 4/20 | 0.56 |
| ▸ | ERCC4 | Q92889 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2266083 | 0.85 | P2RX7 (0.54) | ALDH1A1ERCC1ERCC4P2RX7MAPT | |
| SCHEMBL22803045 | 0.85 | ERCC1 (0.53) | ALDH1A1ERCC1ERCC4NPC1RAB9A | |
| SCHEMBL29334787 | 0.82 | LMNA (0.58) | ALDH1A1LMNAMAPTMAPK1NLRP1 | |
| SCHEMBL2264620 | 0.81 | NPC1 (0.62) | ALDH1A1NPC1RAB9AMAPK1MCL1 | |
| SCHEMBL1143282 | 0.81 | ALDH1A1 (0.64) | ALDH1A1ERCC1ERCC4NPC1RAB9A | |
| SCHEMBL1143378 | 0.80 | ALDH1A1 (0.62) | ALDH1A1ERCC1ERCC4NPC1RAB9A | |
| SCHEMBL17914676 | 0.80 | ALDH1A1 (0.62) | ALDH1A1ERCC1ERCC4NPC1RAB9A | |
| SCHEMBL7241336 | 0.80 | ALDH1A1 (0.62) | ALDH1A1ERCC1ERCC4NPC1RAB9A | |
| SCHEMBL17372538 | 0.78 | ALDH1A1 (0.61) | ALDH1A1ERCC1ERCC4NPC1RAB9A | |
| SCHEMBL12354898 | 0.78 | ALDH1A1 (0.74) | ALDH1A1ERCC1ERCC4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020249821-A1 | NOVEL ARGINASE INHIBITORS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2020-12-17 | — | — | WO | disclosed |
| US-7998986-B2 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998986-B2 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20030181420-A1 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS, INC. | 2003-09-25 | — | — | US | disclosed |
| US-4104273-A | Derivatives of 3-cyano-pyrid-2-ones | ROHM AND HAAS COMPANY (US) | 1978-08-01 | — | — | US | disclosed |
| US-4028084-A | Derivatives of 3-carboxy pyrid-2-ones | ROHM AND HAAS COMPANY (US) | 1977-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181420-A1 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | NR1H2, NR1H3, NCOA1 | ALDH1A1 2744/4885ERCC1 2563/4885ERCC4 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.